Cardiol Therapeutics Inc. (FRA:CT9)
Germany · Delayed Price · Currency is EUR 0.8680
+0.0280 (3.33%)
Last updated: Dec 1, 2025, 8:10 AM CET
Cardiol Therapeutics Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc.
| Country | Canada |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 18 |
| CEO | David Elsley |
Contact Details
Address: 2265 Upper Middle Road East Oakville, Ontario L6H 0G5 Canada | |
| Phone | 289 910 0850 |
| Website | cardiolrx.com |
Stock Details
| Ticker Symbol | CT9 |
| Exchange | Frankfurt Stock Exchange |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Elsley | Chief Executive Officer |
| Christopher Waddick | Chief Financial Officer |
| Bernard Lim | Chief Operating Officer |
| Trevor Burns | Head of Investor Relations |